Key result
Cyclophilin A and its receptor CD147 (EMMPRIN) contribute significantly to cardiovascular inflammation and myocardial remodeling, representing a novel therapeutic target.
Cyclophilin A and its receptor CD147 are identified as potential novel targets for treating vascular and myocardial inflammation.
May identify CyPA-CD147 as a target in myocardial injury; leaves open clinical translation.
Cyclophilin A (CyPA) is an abundantly expressed intracellular protein. It exerts a variety of functions due to its peptidyl-prolyl cis-trans isomerase (PPIase) activity. When released into the extracellular space, CyPA binds to its extracellular receptor CD147 (EMMPRIN) and thereby initiates a cascade of inflammatory processes. Recent data indicate that both extra- and intracellular CyPA significantly contribute to cardiovascular inflammation, myocardial ischaemia and reperfusion injury, and myocardial remodelling processes. Thus, CyPA appears to represent a novel target to treat vascular and myocardial inflammation.
No takes yet. Share an insight, caveat, or question.
Seizer et al. (2014) conducted a review in Cardiovascular diseases. Cyclophilin A (CyPA) and EMMPRIN (CD147) was evaluated. Cyclophilin A and its receptor CD147 (EMMPRIN) contribute significantly to cardiovascular inflammation and myocardial remodeling, representing a novel therapeutic target.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: